Video

Dr. Ruan on Future Research With CAR T-Cell Therapy in MCL

Jia Ruan, MD, PhD, discusses future research with CAR T-cell therapy in mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses future research with CAR T-cell therapy in mantle cell lymphoma (MCL).

In July 2020, the FDA approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus) as a treatment for patients with relapsed/refractory MCL. The approval was based on findings from the phase 2 ZUMA-2 trial in which the CAR T-cell product elicited an 87% objective response rate and a 62% complete response rate in this patient population. Despite the impressive efficacy rate, toxicity remains a concern with CAR T-cell therapy, says Ruan.

Future research efforts with CAR T-cell therapy are looking to bring the modality into earlier lines of therapy, says Ruan. Additionally, combining the therapy with other agents may augment the effectiveness of brexucabtagene autoleucel while minimizing potential toxicities, Ruan explains.

Additional research is also needed to determine which patients are best suited to receive CAR T-cell therapy. Currently, younger, fit patients are eligible; however, finding ways to bring CAR T-cell therapy to older patients with comorbidities is critical because this patient population comprises a large proportion of patients with MCL, concludes Ruan.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity